Please provide your email address to receive an email when new articles are posted on . The FDA on Wednesday approved the first nasal glucagon powder for the emergency treatment of severe hypoglycemia ...

The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray. The FDA Wednesday approved Eli Lilly & Co.’s nasal ...

(HealthDay News) — Nasal glucagon can effectively and efficiently manage moderate or severe hypoglycemic episodes (HEs) in real-world settings in adult patients with type 1 diabetes, according to a ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method for ...